Statistics for C4 Therapeutics (id:8285 CCCC)

Valuation metrics

Market cap

415.77M

Enterprise value

200.40M

Trailing P/E (ttm)

-1.59

Forward P/E

-3.22

PEG ratio

-3.22

Price/Sales (ttm)

12.35

Price/Book (mrq)

1.60

Enterprise Value/Revenue

5.95

Enterprise Value/EBITDA

-1.74

Overview

Shares outstanding

70.59M

Float

47.35M

Shares short

6.65M

% Held by insiders

0.12%

% Held by institutions

0.87%

Average volume (10 days)

1.11M

Average volume (90 days)

Price summary

52-Week low

1.06

52-Week high

11.88

52-Week change

64.71%

Beta

3.06

50-Day moving average

5.96

200-Day moving average

6.47

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

-183.86%

Operational effectiveness

Return on assets

-20.61%

Return on equity

-46.00%

Income statement

Revenue (ttm)

0.52

Revenue per share (ttm)

0.52

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-115,127,000.00

Net income to common (ttm)

-105,497,000.00

Diluted EPS (ttm)

-1.60

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

255.64M

Total cash per share (mrq)

3.62

Total debt (mrq)

67.10M

Total Debt/Equity (mrq)

27.65

Current ratio (mrq)

631.10%

Book value per share (mrq)

3.44

Cash flow

Cash flow statement

-71,234,000.00

Levered free cash flow (LFCF)

-41,839,376.00